Tysabri and PML: What Patients Should Know About Onset and Monitoring

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specific Risk Awareness

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This serious brain infection has been recognized in medical literature for decades, with ongoing pharmacovigilance tracking its occurrence in patients on immunosuppressive therapies. This page reviews the timeline of PML onset, key symptoms to watch for, and monitoring recommendations based on current evidence.

Find Out If You Qualify for Compensation →

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, to communicate this risk. The clinical presentation of PML is variable and can include progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis is based on clinical, radiological, and laboratory findings. In a large retrospective cohort study of 456 PML patients observed between 1987 and 2024, 82.4% had a definite diagnosis and 17.6% had a clinico-radiological diagnosis (https://pubmed.ncbi.nlm.nih.gov/40922664/). The disease is characterized by demyelination in the brain, which can be detected on magnetic resonance imaging (MRI), and confirmation often requires detection of JCV DNA in cerebrospinal fluid or brain tissue.

Mechanism of Action and Risk Factors

The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration from the bloodstream into the central nervous system. This reduces inflammation in conditions like multiple sclerosis but also impairs immune surveillance against JCV. Under normal conditions, JCV is controlled by the immune system, but when immune cell trafficking is blocked, the virus can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. Three key risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1,869 patients with multiple sclerosis treated for a median of 120 weeks, and both had received Tysabri in addition to interferon beta-1a. The third case occurred after eight doses in one of 1,043 patients with Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings and Legal Implications

The adequacy of warnings regarding Tysabri and PML is a central concern in legal and medical contexts. The boxed warning explicitly states that Tysabri increases the risk of PML and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning also advises healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom. Because of the risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether patients and providers were adequately informed about the magnitude of risk, particularly in relation to specific risk factors. For affected patients, settlement-related considerations often involve the timeline between exposure to Tysabri and documented harm. PML can develop after varying durations of treatment, with risk increasing beyond two years of therapy. The clinical trials documented cases after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In legal proceedings, establishing when symptoms first appeared and when PML was diagnosed is critical for linking the harm to Tysabri exposure. The severe outcomes of PML—death or severe disability—underscore the gravity of these cases.

Conclusion: Evidence and Legal Context

In summary, the evidence demonstrates a clear causal link between Tysabri and PML, with established risk factors and a mechanistic basis. The FDA-mandated warnings highlight the serious nature of this adverse event, but legal scrutiny may focus on whether these warnings were sufficient to protect patients. For those affected, understanding the clinical presentation, risk factors, and timeline of harm is essential for evaluating potential claims. References - https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962 - https://pubmed.ncbi.nlm.nih.gov/40922664/

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and what is it used for?

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. It works by binding to alpha-4 integrins on immune cells, preventing their migration into the central nervous system, thereby reducing inflammation. However, this mechanism also increases the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection.

What are the risk factors for developing PML while on Tysabri?

Three key risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk. The FDA boxed warning and the TOUCH Prescribing Program aim to mitigate this risk, but PML can still occur.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.